Nathan Bryson
Direttore Tecnico/Scientifico/R&S presso Reunion Neuroscience, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Joseph del Moral | M | 45 |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Dieter Weinand | M | 63 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 4 anni |
| Edward Gudaitis | M | - | 6 anni | |
| Ellen Lubman | F | 48 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 anni |
| Gregory Mayes | M | 55 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 anni |
| Philippe Savard | M | - | 8 anni | |
| Barry Fishman | M | 67 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 anni |
| Curtis Weber | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 anni |
| Borys Chabursky | M | - | 9 anni | |
| Robert Alexander | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 1 anni |
| Hannan Fleiman | M | 44 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 5 anni |
| Fred Grossman | M | 62 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 1 anni |
| Ansbert Gadicke | M | 66 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Edward Smith | M | 53 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 anni |
| Srini Devadas | M | - |
Massachusetts Institute of Technology
| 36 anni |
| Alex Pentland | M | 72 |
Massachusetts Institute of Technology
| 37 anni |
| Kristen Laguerre | F | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Michael Cima | M | 64 |
Massachusetts Institute of Technology
| 38 anni |
| Michael Cusumano | M | 69 |
Massachusetts Institute of Technology
| 38 anni |
| Jonathan See | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Stephen Willard | M | 63 |
Flamel Technologies SA
 Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Flamel Technologies SA engages in the research, development and commercialization of pharmaceutical products. Its portfolio includes Bloxiverz, Vazculep, Micropump, LiquiTime, Trigger Lock and Medusa. The company was founded by Gérard Soula in August 1990 and is headquartered in Vénissieux, France. | 14 anni |
| Gérard Soula | M | 78 |
Flamel Technologies SA
Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Flamel Technologies SA engages in the research, development and commercialization of pharmaceutical products. Its portfolio includes Bloxiverz, Vazculep, Micropump, LiquiTime, Trigger Lock and Medusa. The company was founded by Gérard Soula in August 1990 and is headquartered in Vénissieux, France. | 15 anni |
| Thomas Kurfess | M | - |
Massachusetts Institute of Technology
| 7 anni |
| Paula Hewitt | F | 52 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Helen Boudreau | F | 58 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 anni |
| Harry Atwater | M | - |
Massachusetts Institute of Technology
| 10 anni |
| David Hill | M | - | 8 anni | |
| David Miller | M | - |
Massachusetts Institute of Technology
| 21 anni |
| Anita Killian | F | - |
Massachusetts Institute of Technology
| 16 anni |
| Tom Rossi | M | 59 | 6 anni | |
| Bruce S. Morra | M | 70 |
Flamel Technologies SA
Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Flamel Technologies SA engages in the research, development and commercialization of pharmaceutical products. Its portfolio includes Bloxiverz, Vazculep, Micropump, LiquiTime, Trigger Lock and Medusa. The company was founded by Gérard Soula in August 1990 and is headquartered in Vénissieux, France. | 7 anni |
| Ronan Levy | M | 45 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Anthony Giovinazzo | M | 67 | 8 anni | |
| Kenneth Howling | M | 66 | 4 anni | |
| Javier de Luis | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Walid Fakhry | M | - |
Massachusetts Institute of Technology
| 6 anni |
| Jeffrey Dennis Sherman | M | 68 | 5 anni | |
| Guo Zhong Xie | M | 64 |
Massachusetts Institute of Technology
| 4 anni |
| Barbara Poggiali | M | 61 |
Massachusetts Institute of Technology
| 5 anni |
| Warren Chen | M | - |
Massachusetts Institute of Technology
| 4 anni |
| Reza Abhari | M | 62 |
Massachusetts Institute of Technology
| 3 anni |
| Gregg Burgess | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Jerry L. Prince | M | - |
Massachusetts Institute of Technology
| 6 anni |
| Mark Jennings | M | 63 |
Massachusetts Institute of Technology
| 5 anni |
| Craig Griffin | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Mehran Mehregany | M | - |
Massachusetts Institute of Technology
| 7 anni |
| Tomer Gold | M | 52 | 3 anni | |
| Ilan Oren | M | 40 | 3 anni | |
| Sung-Hwan Shin | M | 61 |
Massachusetts Institute of Technology
| 7 anni |
| Brian Eric Thompson | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Norma Beauchamp | F | 62 | 5 anni | |
| Kyu-Ha Cung | M | 72 |
Massachusetts Institute of Technology
| 7 anni |
| Tricia Symmes | F | - | 3 anni | |
| Georgios Alexopoulos | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Aura Balboa | F | - | 7 anni | |
| Walid Fakhry | M | - |
Massachusetts Institute of Technology
| 6 anni |
| Antonio Marra | M | 61 |
Massachusetts Institute of Technology
| 6 anni |
| Rakesh Kapoor | M | - |
Massachusetts Institute of Technology
| 4 anni |
| Anastasios Aslidis | M | 64 |
Massachusetts Institute of Technology
| 3 anni |
| Luc Mainville | M | 60 | 2 anni | |
| Brad Feld | M | 58 |
Massachusetts Institute of Technology
| 5 anni |
| John Robert Chisholm | M | - |
Massachusetts Institute of Technology
| 7 anni |
| Thomas H. Lee | M | 64 |
Massachusetts Institute of Technology
| 5 anni |
| Adnan Lawai | M | - |
Massachusetts Institute of Technology
| 7 anni |
| John S. Langford | M | - |
Massachusetts Institute of Technology
| 3 anni |
| Ronald Hosking | M | 79 | 6 anni | |
| Gerry A. Schaafsma | M | - |
Auburn University
| 6 anni |
| Dimitris J. Bertsimas | M | - |
Massachusetts Institute of Technology
| 2 anni |
| Kei Yamamoto | F | - |
Massachusetts Institute of Technology
| 5 anni |
| Bert Richards | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Julia G. Levy | M | 89 | 5 anni | |
| Philippe Laffont | M | - |
Massachusetts Institute of Technology
| 6 anni |
| John Friedrichsen | M | 62 | 4 anni | |
| Matthew Pfeffer | M | 67 | 2 anni | |
| Jonathan R. Coe | M | - |
Auburn University
| 6 anni |
| Perry B. Molinoff | M | 84 | 4 anni | |
| David Tyrrell | M | - | 2 anni | |
| Perry Ha | M | 62 |
Massachusetts Institute of Technology
| 6 anni |
| Ken Kharbanda | M | - |
Massachusetts Institute of Technology
| 3 anni |
| David Busam | M | - |
Auburn University
| 6 anni |
| Subodh Kulkarni | M | 59 |
Massachusetts Institute of Technology
| 4 anni |
| Suresh Thirugnanam | M | 60 |
Massachusetts Institute of Technology
| 4 anni |
| Ford Tamer | M | 62 |
Massachusetts Institute of Technology
| 5 anni |
| Rafael Jorda | M | - |
Flamel Technologies SA
Flamel Technologies SA Pharmaceuticals: MajorHealth Technology Flamel Technologies SA engages in the research, development and commercialization of pharmaceutical products. Its portfolio includes Bloxiverz, Vazculep, Micropump, LiquiTime, Trigger Lock and Medusa. The company was founded by Gérard Soula in August 1990 and is headquartered in Vénissieux, France. | - |
| David E. Culler | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Jon Hirschtick | M | - |
Massachusetts Institute of Technology
| 5 anni |
| Ayman Mahmoud Hindy | M | - |
Massachusetts Institute of Technology
| 4 anni |
| Jinane Abounadi | F | - |
Massachusetts Institute of Technology
| 9 anni |
| Alan Torrie | M | 73 | 7 anni | |
| J. Lievonen | M | - | - | |
| James F. Butler | M | - |
Massachusetts Institute of Technology
| 6 anni |
| Steve Kishi | M | - |
Massachusetts Institute of Technology
| 4 anni |
| Kin Yau Muk | M | 61 |
Massachusetts Institute of Technology
| 1 anni |
| Nelson Chu | M | - |
Massachusetts Institute of Technology
| 2 anni |
| Nicholas L. Abbott | M | - |
Massachusetts Institute of Technology
| 3 anni |
| Michael James Pascutti | M | - |
Massachusetts Institute of Technology
| 4 anni |
| Han Song Cheng | M | 64 |
Massachusetts Institute of Technology
| 4 anni |
| Maiya Shur | F | - |
Massachusetts Institute of Technology
| 14 anni |
| Doug Kirkpatrick | M | - |
Massachusetts Institute of Technology
| 8 anni |
| Michael Franciscus Bos | M | - |
Massachusetts Institute of Technology
| 4 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 58 | 58.00% |
| Canada | 38 | 38.00% |
| Francia | 4 | 4.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Nathan Bryson
- Contatti personali
